Singapore, May 30 -- Singapore-based biopharmaceutical company Specialised Therapeutics (ST) has announced the Australian registration of SKYTROFA(R) (lonapegsomatropin)as a new once-weekly injectable therapy forpaediatric growth hormone deficiency (GHD).

The Therapeutic Goods Administration (TGA) has approved SKYTROFA as a treatment for"growth failure in children and adolescents aged from 3 years up to 18 years due to insufficient endogenous growth hormone secretion".

GHD is a rare disease affecting around 2-3/10,000 Australians, with approximately 2,000 children thought to be living with the condition.The goal of treatment for GHD is to restore normal levels of growth hormone in the body, reduce physical symptoms, enhance metabolic he...